Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline

Journal of Alzheimer's Disease

Volumn 20, Issue SUPPL.1, 2010, Pages

  Cunha, Rodrigo A ^a   Agostinho, Paula M ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

A2A receptors; adenosine; aging; Alzheimer's disease; caffeine; chronic stress; memory

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 PHENYLTHEOPHYLLINE; ADENOSINE A2A RECEPTOR ANTAGONIST; CAFFEINE; ISTRADEFYLLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; THEOPHYLLINE; ADENOSINE RECEPTOR; CENTRAL STIMULANT AGENT;

AGING; ALCOHOL CONSUMPTION; ALERTNESS; ALZHEIMER DISEASE; AMNESIA; APOPTOSIS; ATTENTION; ATTENTION DEFICIT DISORDER; BRAIN METABOLISM; CHRONIC STRESS; COGNITION; CONFERENCE PAPER; CONVULSION; DIETARY INTAKE; HUMAN; MEMORY DISORDER; MOOD; NOCICEPTIVE STIMULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP DEPRIVATION; ANIMAL; BRAIN; BRAIN DISEASE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; MENTAL FUNCTION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BRAIN; BRAIN DISEASES; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEMORY DISORDERS; MENTAL PROCESSES; RECEPTORS, PURINERGIC P1;

EID: 77954537925     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1408     Document Type: Conference Paper

References (322)

1. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51, 83-133.
2. Alsene K, Deckert J, Sand P, de Wit H (2003) Association between A2a receptor gene polymorphisms and caffeineinduced anxiety. Neuropsychopharmacology 28, 1694-1702.
3. Cornelis MC, El-Sohemy A, Campos H (2007) Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr 86, 240-244.
4. Ŕetey JV, Adam M, Khatami R, Luhmann UF, Jung HH, Berger W, Landolt HP (2007) A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 81, 692-698.
5. Childs E, Hohoff C, Deckert J, Xu K, Badner J, de Wit H (2008) Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 33, 2791-2800.
6. Facheris MF, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Rocca WA, Maraganore DM (2008) Coffee, caffeine-related genes, and Parkinsons disease: a casecontrol study. Mov Disord 23, 2033-2040.
7. Rogers PJ, Dernoncourt C (1998) Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. Pharmacol Biochem Behav 59, 1039-1045.
8. Lorist MM, Tops M (2003) Caffeine, fatigue, and cognition. Brain Cogn 53, 82-94.
9. Heatherley SV, Hayward RC, Seers HE, Rogers PJ (2005) Cognitive and psychomotor performance, mood, and pressor effects of caffeine after 4, 6 and 8 h caffeine abstinence. Psychopharmacology (Berl) 178, 461-470.
10. Daly JW (2007) Caffeine analogs: biomedical impact. Cell Mol Life Sci 64, 2153-2169.
11. Rees K, Allen D, Lader M (1999) The influences of age and caffeine on psychomotor and cognitive function. Psychopharmacology (Berl) 145, 181-188.
12. Brice CF, Smith AP (2002) Effects of caffeine on mood and performance: a study of realistic consumption. Psychopharmacology (Berl) 164, 188-192.
13. Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R (2002) Effects of caffeine, sleep loss, and stress on cognitive performance and mood during US Navy SEAL training. Sea-Air-Land. Psychopharmacology (Berl) 164, 250-261.
14. Childs E, deWit H (2006) Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 185, 514-523.
15. Martin FH, Garfield J (2006) Combined effects of alcohol and caffeine on the late components of the event-related potential and on reaction time. Biol Psychol 71, 63-73.
16. Barry RJ, Johnstone SJ, Clarke AR, Rushby JA, Brown CR, McKenzie DN (2007) Caffeine effects on ERPs and performance in an auditory Go/NoGo task. Clin Neurophysiol 118, 2692-2699.
17. Hewlett P, Smith A (2007) Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses. Hum Psychopharmacol 22, 339-350.
18. Cunha RA, Ferŕe S, Vaugeois JM, Chen JF (2008) Potential therapeutic interest of adenosineA2A receptors in psychiatric disorders. Curr Pharm Des 14, 1512-1524.
19. CunhaRA(2008) Caféna, receptores de adenosina, memoria y enfermedad de Alzheimer. Med Clin 131, 790-795.
20. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI (1997) Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37, 693-703.
21. Hogervorst E, Riedel WJ, Kovacs E, Brouns F, Jolles J (1999) Caffeine improves cognitive performance after strenuous physical exercise. Int J Sports Med 20, 354-361.
22. Smit HJ, Rogers PJ (2000) Effects of low doses of caffeine on cognitive performance, mood and thirst in low and higher caffeine consumers. Psychopharmacology (Berl) 152, 167-173.
23. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB (2005) Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) 179, 813-825.
24. van Duinen H, Lorist MM, Zijdewind I (2005) The effect of caffeine on cognitive task performance and motor fatigue. Psychopharmacology (Berl) 180, 539-547.
25. Beaumont M, Batejat D, Pierard C, Coste O, Doireau P, Van Beers P, Chauffard F, Chassard D, Enslen M, Denis JB, Lagarde D(2001) Slow release caffeine and prolonged (64-h) continuous wakefulness: effects on vigilance and cognitive performance. J Sleep Res 10, 265-276.
26. Patat A, Rosenzweig P, Enslen M, Trocherie S, Miget N, Bozon MC, Allain H, Gandon JM (2000) Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep-deprived subjects. Hum Psychopharmacol 15, 153-170.
27. Jarvis MJ (1993) Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology (Berl) 110, 45-52.
28. Hameleers PA, Van Boxtel MP, Hogervorst E, Riedel WJ, Houx PJ, Buntinx F, Jolles J (2000) Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol 15, 573-581.
29. Johnson-Kozlow M, Kritz-Silverstein D, Barrett-Connor E, Morton D (2002) Coffee consumption and cognitive function among older adults. Am J Epidemiol 156, 842-850.
30. James JE, Rogers PJ (2005) Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation. Psychopharmacology (Berl) 182, 1-8.
31. James JE, Keane MA (2007) Caffeine, sleep and wakefulness: implications of new understanding about withdrawal reversal. Hum Psychopharmacol 22, 549-558.
32. Schmitt JA, Hogervorst E, Vuurman EF, Jolles J, Riedel WJ (2003) Memory functions and focussed attention in middleaged and elderly subjects are unaffected by a low, acute dose of caffeine. J Nutr Health Aging 7, 301-303.
33. Bichler A, Swenson A, Harris MA (2006) A combination of caffeine and taurine has no effect on short term memory but induces changes in heart rate and mean arterial blood pressure. Amino Acids 31, 471-476.
34. Bonnet MH, Balkin TJ, Dinges DF, Roehrs T, Rogers NL, Wesensten NJ; Sleep Deprivation and Stimulant Task Force of the American Academy of Sleep Medicine (2005) The use of stimulants to modify performance during sleep loss: a review by the sleep deprivation and Stimulant Task Force of the American Academy of Sleep Medicine. Sleep 28, 1163-1187.
35. van Boxtel MP, Schmitt JA, Bosma H, Jolles J (2003) The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav 75, 921-927.
36. Cestari V, Castellano C (1996) Caffeine and cocaine interaction on memory consolidation in mice. Arch Int Pharmacodyn Ther 331, 94-104.
37. Angelucci ME, Vital MA, Cesario C, Zadusky CR, Rosalen PL, da Cunha C (1999) The effect of caffeine in animal models of learning and memory. Eur J Pharmacol 373, 135-140.
38. Angelucci ME, Cesario C, Hiroi RH, Rosalen PL, da Cunha C (2002) Effects of caffeine on learning and memory in rats tested in the Morris water maze. Braz J Med Biol Res 35, 1201-1208.
39. Hauber W, Bareiss A (2001) Facilitative effects of an adenosine A1/A2 receptor blockade on spatial memory performance of rats: selective enhancement of reference memory retention during the light period. Behav Brain Res 118, 43-52.
40. Prediger RD, Batista LC, Takahashi RN (2005) Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol Aging 26, 957-964.
41. Costa MS, Botton PH, Mioranzza S, Souza DO, Porcíuncula LO (2008) Caffeine prevents age-associated recognition memory decline and changes brain-derived neurotrophic factor and tyrosine kinase receptor (TrkB) content in mice. Neuroscience 153, 1071-1078.
42. Zarrindast MR, Shafaghi B (1994) Effects of adenosine receptor agonists and antagonists on acquisition of passive avoidance learning. Eur J Pharmacol 256, 233-239.
43. Corodimas KP, Pruitt JC, Stieg JM (2000) Acute exposure to caffeine selectively disrupts context conditioning in rats. Psychopharmacology (Berl) 152, 376-382.
44. Furusawa K (1991) Drug effects on cognitive function in mice determined by the non-matching to sample task using a 4-arm maze. Jpn J Pharmacol 56, 483-493.
45. DallIgna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR(2007) Caffeine and adenosineA2a receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 203, 241-245.
46. Takahashi RN, Pamplona FA, Prediger RD (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 13, 2614-2632.
47. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM (2005) Adenosine and brain function. Int Rev Neurobiol 63, 191-270.
48. Lelo A, Birkett DJ, Robson RA, Miners JO (1986) Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol 22, 177-182.
49. Kaplan GB, Greenblatt DJ, Leduc BW, Thompson ML, Shader RI (1989) Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther 248, 1078-1083.
50. Denaro CP, Brown CR, Wilson M, Jacob P 3rd, Benowitz NL (1990) Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 48, 277-285.
51. Chou T (1992) Wake up and smell the coffee. Caffeine, coffee, and the medical consequences. West J Med 157, 544-553.
52. Benowitz NL, Jacob P 3rd, Mayan H, Denaro C (1995) Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 58, 684-691.
53. Simola N, Morelli M, Seeman P (2008) Increase of Dopamine D2High receptors in the striatum of rats sensitized to caffeine motor effects. Synapse 62, 394-397.
54. Spinetta MJ,Woodlee MT, Feinberg LM, Stroud C, Schallert K, Cormack LK, Schallert T (2008) Alcohol-induced retrograde memory impairment in rats: prevention by caffeine. Psychopharmacology (Berl) 201, 361-371.
55. Yoshimura H (2005) The potential of caffeine for functional modification from cortical synapses to neuron networks in the brain. Curr Neuropharmacol 3, 309-316.
56. Yu L, Coelho J, Zhang X, Fu Y, Tillman A, Karaoz U, Fredholm BB, Weng Z, Chen JF (2009) Uncovering multiple molecular targets for caffeine by a drug target validation strategy of combined A2A receptor knockouts and microarray profiling. Physiol Gen 37, 199-210.
57. Soellner DE, Grandys T, Nuñez JL (2009) Chronic prenatal caffeine exposure impairs novel object recognition and radial arm maze behaviors in adult rats. Behav Brain Res 205, 191-199.
58. Daly JW, Fredholm BB (1988) Caffeine-an atypical drug of dependence. Drug Alcohol Depend 51, 199-206.
59. Cunha RA (2008) Different cellular sources and different roles of adenosine: A1 receptor-mediated inhibition through astrocytic-driven volumetransmission and synapse-restricted A2A receptor-mediated facilitation of plasticity. Neurochem Int 52, 65-72.
60. de Mendonca A, Ribeiro JA (1990) 2-Chloroadenosine decreases long-term potentiation in the hippocampal CA1 area of the rat. Neurosci Lett 118, 107-111.
61. de Mendonca A, Ribeiro JA (1994) Endogenous adenosine modulates long-term potentiation in the hippocampus. Neuroscience 62, 385-390.
62. de Mendonca A, Almeida T, Bashir ZI, Ribeiro JA (1997) Endogenous adenosine attenuates long-term depression and depotentiation in the CA1 region of the rat hippocampus. Neuropharmacology 36, 161-167.
63. Forghani R, Krnjevíc K (1995) Adenosine antagonists have differential effects on induction of long-term potentiation in hippocampal slices. Hippocampus 5, 71-77.
64. Zhang C, Schmidt JT (1998) AdenosineA1 receptors mediate retinotectal presynaptic inhibition: uncoupling by C-kinase and role in LTP during regeneration. J Neurophysiol 79, 501-510.
65. Fujii S, Kuroda Y, Ito K, Kaneko K, Kato H (1999) Effects of adenosine receptors on the synaptic and EPSP-spike components of long-term potentiation and depotentiation in the guinea-pig hippocampus. J Physiol 521, 451-466.
66. Huang CC, Liang YC, Hsu KS (1999) A role for extracellular adenosine in time-dependent reversal of long-term potentiation by low-frequency stimulation at hippocampal CA1 synapses. J Neurosci 19, 9728-9738.
67. Bon CL, Garthwaite J (2002) Adenosine acting on A1 receptors protects NO-triggered rebound potentiation and LTP in rat hippocampal slices. J Neurophysiol 87, 1781-1789.
68. Kukley M, Schwan M, Fredholm BB, Dietrich D (2005) The role of extracellular adenosine in regulating mossy fiber synaptic plasticity. J Neurosci 25, 2832-2837.
69. Rex CS, Kraḿar EA, Colgin LL, Lin B, Gall CM, Lynch G (2005) Long-term potentiation is impaired in middle-aged rats: regional specificity and reversal by adenosine receptor antagonists. J Neurosci 25, 5956-5966.
70. dAlcantara P, Ledent C, Swillens S, Schiffmann SN (2001) Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107, 455-464.
71. Fontinha BM, Díogenes MJ, Ribeiro JA, Sebastião AM (2008) Enhancement of long-term potentiation by brainderived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology 54, 924-933.
72. Rebola N, Lujan R, Cunha RA, Mulle C (2008) Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 57, 121-134.
73. Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY, Takano H, Moss SJ, McCarthy K, Haydon PG (2005) Astrocytic purinergic signaling coordinates synaptic networks. Science 310, 113-116.
74. Cunha RA, Correia-de-Śa P, Sebastião AM, Ribeiro JA (1996) Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. Br J Pharmacol 119, 253-260.
75. Wieraszko A, Goldsmith G, Seyfried TN(1989) Stimulationdependent release of adenosine triphosphate from hippocampal slices. Brain Res 485, 244-250.
76. Cunha RA, Vizi ES, Ribeiro JA, Sebastião AM (1996) Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high-but not low-frequency stimulation of rat hippocampal slices. J Neurochem 67, 2180-2187.
77. Pankratov Y, Lalo U, Verkhratsky A, North RA (2007) Quantal release of ATP in mouse cortex. J Gen Physiol 129, 257-265.
78. Lynch GS, Dunwiddie T, Gribkoff V (1977) Heterosynaptic depression: a postsynaptic correlate of long-term potentiation. Nature 266, 737-739.
79. Serrano A, Haddjeri N, Lacaille JC, Robitaille R (2006) GABAergic network activation of glial cells underlies hippocampal heterosynaptic depression. J Neurosci 26, 5370-5382.
80. Collingridge GL, Singer W (1990) Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci 11, 290-296.
81. Gillessen T, Budd SL, Lipton SA (2002) Excitatory amino acid neurotoxicity. Adv Exp Med Biol 513, 3-40.
82. Babkoff H, French J, Whitmore J, Sutherlin R (2002) Singledose bright light and/or caffeine effect on nocturnal performance. Aviat Space Environ Med 73, 341-350.
83. Childs E, de Wit H (2008) Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals. Exp Clin Psychopharmacol 16, 13-21.
84. Hogervorst E, Bandelow S, Schmitt J, Jentjens R, Oliveira M, Allgrove J, Carter T, Gleeson M (2008) Caffeine improves physical and cognitive performance during exhaustive exercise. Med Sci Sports Exerc 40, 1841-1851.
85. Rogers PJ, Heatherley SV, Hayward RC, Seers HE, Hill J, Kane M (2005) Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction. Psychopharmacology (Berl) 179, 742-752.
86. Costenla AR, Díogenes MJ, Ribeiro JA, Cunha RA, de Mendonca A (2008) Enhanced role of adenosine A2A receptors on long-term potentiation in the rat hippocampus upon aging. Soc Neurosci Abstr, Program No. 541.18.
87. Normile HJ, Barraco RA (1991) N6-cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors. Brain Res Bull 27, 101-104.
88. von Lubitz DK, Paul IA, Bartus RT, Jacobson KA (1993) Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory. Eur J Pharmacol 249, 271-280.
89. Corodimas KP, Tomita H (2001) Adenosine A1 receptor activation selectively impairs the acquisition of contextual fear conditioning in rats. Behav Neurosci 115, 1283-1290.
90. Prediger RD, Takahashi RN (2005) Modulation of short-term social memory in rats by adenosine A1 and A2A receptors. Neurosci Lett 376, 160-165.
91. Fraser CM, Fisher A, Cooke MJ, Thompson ID, Stone TW (1997) Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology (Berl) 130, 334-342.
92. Pereira GS, Mello-Souza T, Vinade ER, Choi H, Rodrigues C, Battastini AM, Izquierdo I, Sarkis JJ, Bonan CD (2002) Blockade of adenosineA1 receptors in the posterior cingulate cortex facilitates memory in rats. Eur J Pharmacol 437, 151-154.
93. Pitsikas N, Borsini F (1997) The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat. Eur J Pharmacol 328, 19-22.
94. Kopf SR, Melani A, Pedata F, Pepeu G (1999) Adenosine and memory storage: effect of A1 and A2 receptor antagonists. Psychopharmacology (Berl) 146, 214-219.
95. Pereira GS, Rossato JI, Sarkis JJ, Cammarota M, Bonan CD, Izquierdo I (2005) Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiol Learn Mem 83, 217-223.
96. Gimenez-Llort L, Masino SA, Diao L, Fernandez-Teruel A, Tobena A, Halldner L, Fredholm BB (2005) Mice lacking the adenosine A1 receptor have normal spatial learning and plasticity in the CA1 region of the hippocampus, but they habituate more slowly. Synapse 57, 8-16.
97. Wang JH, Ma YY, van den Buuse M(2006) Improved spatial recognition memory in mice lacking adenosine A2A receptors. Exp Neurol 199, 438-445.
98. Gimenez-Llort L, Schiffmann SN, Shmidt T, Canela L, Camon L, Wassholm M, Canals M, Terasmaa A, Fernandez-Teruel A, Tobena A, Popova E, Ferre S, Agnati L, Ciruela F, Martinez E, Scheel-Kruger J, Lluis C, Franco R, Fuxe K, Bader M (2007) Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol Learn Mem 87, 42-56.
99. Normile HJ, Gaston S, Johnson G, Barraco RA (1994) Activation of adenosine A1 receptors in the nucleus accumbens impairs inhibitory avoidance memory. Behav Neural Biol 62, 163-166.
100. Hooper N, Fraser C, Stone TW (1996) Effects of purine analogues on spontaneous alternation in mice. Psychopharmacology (Berl) 123, 250-257.
101. Ohno M, Watanabe S (1996) Working memory failure by stimulation of hippocampal adenosine A1 receptors in rats. Neuroreport 7, 3013-3016.
102. Yang JN, Björklund O, Lindström-Törnqvist K, Lindgren E, Eriksson TM, Kahlström J, Chen JF, Schwarzschild MA, Tobler I, Fredholm BB (2009) Mice heterozygous for both A1 and A2A adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol 106, 631-639.
103. Yang JN, Chen JF, Fredholm BB (2009) Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol 296, H1141-H1149.
104. von Arnim CA, Timmler M, Ludolph AC, Riepe MW(2000) Adenosine receptor up-regulation: initiated upon preconditioning but not upheld. Neuroreport 11, 1223-1226.
105. Zhou AM, Li WB, Li QJ, Liu HQ, Feng RF, Zhao HG (2004) A short cerebral ischemic preconditioning upregulates adenosine receptors in the hippocampal CA1 region of rats. Neurosci Res 48, 397-404.
106. Cunha RA (2005) Neuroprotection by adenosine in the brain: fromA1 receptor activation to A2A receptor blockade. Purinergic Signal 1, 111-134.
107. Quarta D, Ferŕe S, Solinas M, You ZB, Hockemeyer J, Popoli P, Goldberg SR (2004) Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem 88, 1151-1158.
108. Ferŕe S (2008) An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem 105, 1067-1079.
109. Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M,Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA, Chase TN (2003) Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinsons disease. Neurology 61, S97-S100.
110. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinsons disease. Trends Neurosci 29, 647-654.
111. RossGW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283, 2674-2679.
112. Ascherio A, Zhang SM, Herńan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinsons disease in men and women. Ann Neurol 50, 56-63.
113. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE (2003) Caffeine, postmenopausal estrogen, and risk of Parkinsons disease. Neurology 60, 790-795.
114. Ascherio A, Weisskopf MG, OReilly EJ, McCullough ML, Calle EE, Rodriguez C, Thun MJ (2004) Coffee consumption, gender, and Parkinsons disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 160, 977-984.
115. Sääksjärvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Männistö S (2008) Prospective study of coffee consumption and risk of Parkinsons disease. Eur J Clin Nutr 62, 908-915.
116. Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A2A receptor antagonists in Parkinsons disease. Pharmacol Ther 105, 267-310.
117. Kalda A, Yu L, Oztas E, Chen JF (2006) Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinsons disease. J Neurol Sci 248, 9-15.
118. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA (2007) Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 83, 293-309.
119. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinsons disease. Ann NY Acad Sci 991, 189-198.
120. Gevaerd MS, Takahashi RN, Silveira R, Da Cunha C (2001) Caffeine reverses the memory disruption induced by intranigral MPTP-injection in rats. Brain Res Bull 55, 101-106.
121. Prediger RD, da Cunha C, Takahashi RN(2005) Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpinetreated rats. Behav Pharmacol 16, 209-218.
122. Müller-Vahl KR, Buddensiek N, Geomelas M, Emrich HM (2008) The influence of different food and drink on tics in Tourette syndrome. Acta Paediatr 97, 442-446.
123. Lara DR, DallIgna OP, Ghisolfi ES, Brunstein MG (2006) Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 30, 617-629.
124. McEwen BS, Sapolsky RM(1995) Stress and cognitive function. Curr Opin Neurobiol 5, 205-216.
125. Cunha GMA, Canas PM, Oliveira CR, Cunha RA (2006) Increased density and synapto-protective effect of adenosine A2A receptors upon sub-chronic restraint stress. Neuroscience 141, 1775-1781.
126. Cunha RA, Cognato GP, Kaster MP, Duarte JMN, Canas PM (2008) Chronic caffeine consumption prevents memory deficits in animal models of diabetic neuropathy, chronic unpredictable stress or juvenile convulsions. Soc Neurosci Abstr, Program No. 291.2.
127. Alzoubi KH, Abdul-Razzak K, Khabour O, Al-Tuweiq G, Alkadhi K (2008) Chronic caffeine administration prevents stress-induced impairment of hippocampus-dependent memory. Soc Neurosci Abstr, Program No. 291.25.
128. Harris A, Ursin H, Murison R, Eriksen HR (2007) Coffee, stress and cortisol in nursing staff. Psychoneuroendocrinology 32, 322-330.
129. Steptoe A, Gibson EL, Vuononvirta R, Williams ED, Hamer M, Rycroft JA, Erusalimsky JD, Wardle J (2007) The effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind trial. Psychopharmacology (Berl) 190, 81-89.
130. Yamato T, Yamasaki S, Misumi Y, Kino M, Obata T, Aomine M (2002) Modulation of the stress response by coffee: an in vivo microdialysis study of hippocampal serotonin and dopamine levels in rat. Neurosci Lett 332, 87-90.
131. Smith AP (2009) Caffeine, cognitive failures and health in a non-working community sample. Hum Psychopharmacol 24, 29-34.
132. Helmstaedter C, Kockelmann E (2006) Cognitive outcomes in patients with chronic temporal lobe epilepsy. Epilepsia 47(Suppl 2), 96-98.
133. Hoppe C, Elger CE, Helmstaedter C (2007) Long-term memory impairment in patients with focal epilepsy. Epilepsia 48(Suppl 9), 26-29.
134. Cognato GP, Agostinho PM, Hockemeyer J, Müller CE, Souza DO, Cunha RA (2010) Caffeine and adenosine A2A receptor antagonists prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. J Neurochem 112, 543-562.
135. Johansson B, Georgiev V, Kuosmanen T, Fredholm BB (1996) Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline-and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. Eur J Neurosci 8, 2447-2458
136. Rigoulot MA, Leroy C, Koning E, Ferrandon A, Nehlig A (2003) Prolonged low-dose caffeine exposure protects against hippocampal damage but not against the occurrence of epilepsy in the lithium-pilocarpine model in the rat. Epilepsia 44, 529-535
137. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM (2008) Evidence for the involvement of the adenosine A2A receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine. Neuropharmacology 55, 35-40.
138. Homayoun H, Khavandgar S, Zarrindast MR (2001) Effects of adenosine receptor agonists and antagonists on pentylenetetrazole-induced amnesia. Eur J Pharmacol 430, 289-294.
139. Convit A,Wolf OT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci U S A 100, 2019-2022.
140. Biessels GJ, Staekenborg S, Brunner E, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic study. Lancet Neurol 5, 64-74.
141. Messier C (2006) Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging 26S, S26-S30.
142. van Dam RM, Hu FB (2005) Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 294, 97-104.
143. Duarte JMN, Carvalho RA, Cunha RA, Gruetter R (2009) Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. J Neurochem 111, 368-379.
144. Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1996) Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 45, 1259-1266.
145. Duarte JMN, Oliveira CR, Ambŕosio AF, Cunha RA (2006) Modification of adenosine A1 and A2A receptor density in the hippocampus of streptozotocin-induced diabetic rats. Neurochem Int 48, 144-150.
146. Castellanos FX, Sonuga-Barke EJ, Milham MP, Tannock R (2006) Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci 10, 117-123.
147. Schnackenberg RC (1975) Caffeine therapy for hyperkinetic children. Curr Psychiatr Ther 15, 39-44.
148. Dalby JT (1985) Will population decreases in caffeine consumption unveil attention deficit disorders in adults? Med Hypotheses 18, 163-167.
149. Garfinkel BD, Webster CD, Sloman L (1975) Individual responses to methylphenidate and caffeine in children with minimal brain dysfunction. Can Med Assoc J 113, 729-732.
150. Garfinkel BD, Webster CD, Sloman L (1981) Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder. Can J Psychiatry 26, 395-401.
151. Gross MD (1975) Caffeine in the treatment of children with minimal brain dysfunction or hyperkinetic syndrome. Psychosomatics 16, 26-27.
152. Arnold LE, Christopher J, Huestis R, Smeltzer DJ (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes analysis. Arch Gen Psychiatry 35, 463-473.
153. Firestone P, Davey J, Goodman JT, Peters S (1978) The effects of caffeine and methylphenidate on hyperactive children. J Am Acad Child Psychiatry 17, 445-456.
154. Leon MR (2000) Effects of caffeine on cognitive, psychomotor, and affective performance of children with Attention-Deficit/Hyperactivity Disorder. J Atten Disord 4, 27-47.
155. el-Yazigi A, Shabib S, al-Rawithi S, Yusuf A, Legayada ES, al-Humidan A (1999) Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases. J Clin Pharmacol 39, 366-372.
156. Pariente-Khayat A, Pons G, Rey E, Richard MO, DAthis P, Moran C, Badoual J, Olive G (1991) Caffeine acetylator phenotyping during maturation in infants. Pediatr Res 29, 492-495.
157. Davids E, Zhang K, Tarazi FI, Baldessarini RJ (2003) Animal models of attention-deficit hyperactivity disorder. Brain Res Rev 42, 1-21.
158. Prediger RD, Pamplona FA, Fernandes D, Takahashi RN (2005) Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) the spontaneously hypertensive rat (SHR). Int J Neuropsychopharmacol 8, 583-594.
159. Prediger RD, Fernandes D, Takahash RN (2005) Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behav Brain Res 159, 197-205.
160. Pires VA, Pamplona FA, Pandolfo P, Fernandes D, Prediger RD, Takahashi RN (2009) Adenosine receptor antagonists improve short-term object-recognition ability of spontaneously hypertensive rats: a rodent model of attention-deficit hyperactivity disorder. Behav Pharmacol 20, 134-145.
161. White AM, Matthews DB, Best PJ (2000) Ethanol, memory, and hippocampal function: a review of recent findings. Hippocampus 10, 88-93.
162. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM (2003) Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade. Neuropharmacology 45, 977-985.
163. Thorsell A, Johnson J, Heilig M (2007) Effect of the adenosine A2a receptor antagonist 3,7-dimethylpropargylxanthine on anxiety-like and depression-like behavior and alcohol consumption inWistar Rats. Alcohol Clin Exp Res 31, 1302-1307.
164. Murray JB (1988) Psychophysiological aspects of caffeine consumption. Psychol Rep 62, 575-587.
165. Nehlig A, Daval JL, Debry G (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 17, 139-170.
166. Roehrs T, Roth T (2008) Caffeine: sleep and daytime sleepiness. Sleep Med Rev 12, 153-162.
167. Calamaro CJ, Mason TB, Ratcliffe SJ (2009) Adolescents living the 24/7 lifestyle: effects of caffeine and technology on sleep duration and daytime functioning. Pediatrics 123, e1005-e1010.
168. Wilson MA (2002) Hippocampal memory formation, plasticity, and the role of sleep. Neurobiol Learn Mem 78, 565-569.
169. Walker MP, Stickgold R (2004) Sleep-dependent learning and memory consolidation. Neuron 44, 121-133.
170. Walker MP, Stickgold R (2006) Sleep, memory, and plasticity. Annu Rev Psychol 57, 139-166.
171. Chee MW, Chuah LY (2008) Functional neuroimaging insights into how sleep and sleep deprivation affect memory and cognition. Curr Opin Neurol 21, 417-423.
172. Alhaider IA, Aleisa AM, Tran TT, Srivareerat M, Alzoubi KH, Alkadhi KA (2008) Caffeine prevents the impairment of the spatial learning and memory induced by sleep deprivation. Soc Neurosci Abstr, Program No. 485.29.
173. Killgore WD, Kahn-Greene ET, Grugle NL, Killgore DB, Balkin TJ (2009) Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32, 205-216.
174. Morrison JH, Hof PR (2002) Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimers disease. Prog Brain Res 136, 467-486.
175. Buckner RL (2004) Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44, 195-208.
176. Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain. Nat Rev Neurosci 7, 30-40.
177. Mahncke HW, Bronstone A, Merzenich MM (2006) Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. Prog Brain Res 157, 81-109.
178. Pagonopoulou O, Angelatou F (1992) Reduction of A1 adenosine receptors in cortex, hippocampus and cerebellum in ageing mouse brain. Neuroreport 3, 735-737.
179. Cunha RA, Constantino MC, Sebastião AM, Ribeiro JA (1995) Modification of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport 6, 1583-1588.
180. Sperĺagh B, Zsilla G, Baranyi M, Ḱekes-Szab́o A, Vizi ES (1997) Age-dependent changes of presynaptic neuromodulation via A1-adenosine receptors in rat hippocampal slices. Int J Dev Neurosci 15, 739-747.
181. Sebastião AM, Cunha RA, de Mendonca A, Ribeiro JA (2000) Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. Br J Pharmacol 131, 1629-1634.
182. Cunha RA, Constantino MD, Fonseca E, Ribeiro JA (2001) Age-dependent decrease in adenosine A1 receptor binding sites in the rat brain. Effect of cis unsaturated free fatty acids. Eur J Biochem 268, 2939-2947.
183. Lopes LV, Cunha RA, Ribeiro JA (1999) Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats. J Neurochem 73, 1733-1738.
184. Rebola N, Sebastião AM, de Mendonca A, Oliveira CR, Ribeiro JA, Cunha RA (2003) Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J Neurophysiol 90, 1295-1303.
185. Canas PM, Duarte JMN, Rodrigues RJ, Köfalvi A, Cunha RA (2009) Modification upon aging of the density of presynaptic modulation systems in the hippocampus. Neurobiol Aging 30, 1877-1884.
186. Rodrigues RJ, Canas PM, Lopes LV, Oliveira CR, Cunha RA (2008) Modification of adenosine receptor modulation of acetylcholine release in the hippocampus of aged rats. Neurobiol Aging 29, 1597-1601.
187. Cunha RA, Almeida T, Ribeiro JA (2001) Parallel modification of adenosine extracellular metabolism and modulatory action in the hippocampus of aged rats. J Neurochem 76, 372-382.
188. Barnes CA(1994) Normal aging: regionally specific changes in hippocampal synaptic transmission. Trends Neurosci 17, 13-18.
189. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 69, 536-545.
190. Laitala VS, Kaprio J, Koskenvuo M, Räihä I, Rinne JO, Silventoinen K (2009) Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 90, 640-646.
191. Selkoe DJ (2001) Alzheimers disease: genes, proteins, and therapy. Physiol Rev 81, 741-766.
192. Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimers disease? Eur J Neurol 9, 377-382.
193. EskelinenMH,NganduT,Tuomilehto J, Soininen H, Kivipelto M (2009) Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 16, 85-91.
194. Parkinson FE, Rudolphi KA, Fredholm BB (1994) Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen Pharmacol 25, 1053-1058.
195. Kittner B (1999) Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord 13(Suppl 3), S166-S171.
196. Marcusson J, Rother M, Kittner B, Rössner M, Smith RJ, Babic T, Folnegovic-Smalc V,Möller HJ, Labs KH (1997) A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord 8, 320-328.
197. Frampton M, Harvey RJ, Kirchner V (2003) Propentofylline for dementia. Cochrane Database Syst Rev, CD002853.
198. Chen X, Gawryluk JW, Wagener JF, Ghribi O, Geiger JD (2008) Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimers disease. J Neuroinflammation 5, 12-20.
199. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J (2006) Caffeine protects Alzheimers mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142, 941-952.
200. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tan J, Citron BA, Lin X, Echeverria V, Potter H (2009) Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimers disease mice. J Alzheimers Dis 17, 661-680.
201. van Dam D, de Deyn PP (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5, 956-970.
202. Götz J, Ittner LM (2008) Animal models of Alzheimers disease and frontotemporal dementia. Nat Rev Neurosci 9, 532-544.
203. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 297, 353-356.
204. Klein WL, Stine WB Jr, Teplow DB (2004) Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimers disease. Neurobiol Aging 25, 569-580.
205. Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F (2000) Modeling Alzheimers disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol 35, 831-841.
206. Chauhan NB, Siegel GJ, Feinstein DL (2005) Propentofylline attenuates tau hyperphosphorylation in Alzheimers Swedish mutant model Tg2576. Neuropharmacology 48, 93-104.
207. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H (2009) Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimers disease transgenic mice. J Alzheimers Dis 17, 681-697.
208. DallIgna OP, Porcíuncula LO, Souza DO, Cunha RA, Lara DR (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138, 1207-1209.
209. Cunha GM, Canas PM, Melo CS, Hockemeyer J, Müller CE, Oliveira CR, Cunha RA (2008) Adenosine A2A receptor blockade prevents memory dysfunction caused by betaamyloid peptides but not by scopolamine or MK-801. Exp Neurol 210, 776-781.
210. Canas PM, Porcíuncula LO, Cunha GMA, Silva CG, Machado NJ, Oliveira JMA, Oliveira CR, Cunha RA (2009) Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by α-amyloid peptides via p38 MAPK kinase pathway. J Neurosci 29, 14741-14751.
211. Albasanz JL, Perez S, Barrachina M, Ferrer I, Mart́n M (2008) Up-regulation of adenosine receptors in the frontal cortex in Alzheimers disease. Brain Pathol 18, 211-219.
212. Angulo E, Casad́o V, Mallol J, Canela EI, Viñals F, Ferrer I, Lluis C, Franco R (2003) A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimers disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol 13, 440-451.
213. Rebola N, Canas PM, Oliveira CR, Cunha RA (2005) Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience 132, 893-903.
214. Selkoe DJ (2002) Alzheimers disease is a synaptic failure. Science 298, 789-791.
215. Coleman P, Federoff H, Kurlan R (2004) A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63, 1155-1162.
216. Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimers disease and mild cognitive impairment. Neurobiol Aging 27, 1372-1384.
217. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501-1508.
218. de Oliveira RV, DallIgna OP, Tort AB, Schuh JF, Neto PF, Santos Gomes MW, Souza DO, Lara DR (2005) Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. Behav Pharmacol 16, 79-84.
219. Bespalov A, Dravolina O, Belozertseva I, Adamcio B, Zvartau E (2006) Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists. Behav Pharmacol 17, 295-302.
220. DallIgna OP, Da Silva AL, Dietrich MO, Hoffmann A, de Oliveira RV, Souza DO, Lara DR (2003) Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-D-aspartate receptor antagonist MK-801 in mice. Psychopharmacology (Berl) 166, 258-263.
221. Zhang DS, Ren LM (2003) Effect of adenosine A1 receptor antagonist on learning and memory and analysis of its mechanism. Yao Xue Xue Bao 38, 416-419.
222. Riedel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J (1995) Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 122, 158-168.
223. Suzuki F, Shimada J, Shiozaki S, Ichikawa S, Ishii A, Nakamura J, Nonaka H, Kobayashi H, Fuse E (1993) Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine-or N6-®- phenylisopropyladenosine-induced cognitive disturbance. J Med Chem 36, 2508-2518.
224. Maemoto T, Tada M, Mihara T, Ueyama N, Matsuoka H, Harada K, Yamaji T, Shirakawa K, Kuroda S, Akahane A, Iwashita A, Matsuoka N, Mutoh S (2004) Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci 96, 42-52.
225. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163, 495-529.
226. Sarter M, Bruno JP (2004) Developmental origins of the agerelated decline in cortical cholinergic function and associated cognitive abilities. Neurobiol Aging 25, 1127-1139.
227. Jin S, Fredholm BB (1997) Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedebergs Arch Pharmacol 355, 48-56.
228. Coleman MP, Perry VH (2002) Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25, 532-537.
229. Luo L, OLeary DD (2005) Axon retraction and degeneration in development and disease. Annu Rev Neurosci 28, 127-156.
230. Wishart TM, Parson SH, Gillingwater TH (2006) Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol 65, 733-739.
231. Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN (1991) Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40, 133-158.
232. Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR, Mugnaini E, Deutch AY, Sesack SR, Arbuthnott GW, Surmeier DJ (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nature Neurosci 9, 251-259.
233. Li H, Li SH, Yu ZX, Shelbourne P, Li XJ (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntingtons disease mice. J Neurosci 21, 8473-8481.
234. Li JY, Plomann M, Brundin P (2003) Huntingtons disease: a synaptopathy? Trends Mol Med 9, 414-420.
235. Ferrer I (2002) Synaptic pathology and cell death in the cerebellum in Creutzfeldt-Jakob disease. Cerebellum 1, 213-222.
236. Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, DEmilia DM, Friedlander RM, Yuan J, Masliah E, Lipton SA (2002) Caspase cascades in human immunodeficiency virusassociated neurodegeneration. J Neurosci 22, 4015-4024.
237. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF (2006) Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 81, 47-63.
238. Gaspar JM, Baptista FI, Galvão J, Castilho A, Cunha RA, Ambŕosio AF (2008) Diabetes alters the content of synaptic proteins in hippocampal nerve terminals. Soc Neurosci Abstr, Program No. 26.13.
239. van Guilder HD, Brucklacher RM, Patel K, Ellis RW, Freeman WM, Barber AJ. (2008) Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina. Eur J Neurosci 28, 1-11.
240. Berliocchi L, Fava E, Leist M, Horvat V, Dinsdale D, Read D, Nicotera P (2005) Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis. J Cell Biol 168, 607-618.
241. Raff MC, Whitmore AV, Finn JT (2002) Axonal selfdestruction and neurodegeneration. Science 296, 868-871.
242. Cowan CM, Thai J, Krajewski S, Reed JC, Nicholson DW, Kaufmann SH, Roskams AJ (2001) Caspases 3 and 9 send a pro-apoptotic signal from synapse to cell body in olfactory receptor neurons. J Neurosci 21, 7099-7109.
243. Greenwood SM, Mizielinska SM, Frenguelli BG, Harvey J, Connolly CN (2007) Mitochondrial dysfunction and dendritic beading during neuronal toxicity. J Biol Chem 282, 26235-26244.
244. Silva CG, Porcíuncula LO, Canas PM, Oliveira CR, Cunha RA (2007) Blockade of adenosine A2A receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiol Dis 27, 182-189.
245. Rebola N, Rodrigues RJ, Lopes LV, Richardson PJ, Oliveira CR, Cunha RA (2005) Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. Neuroscience 133, 79-83.
246. Davey GP, Peuchen S, Clark JB (1998) Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem 273, 12753-12757.
247. Battino M, Quiles JL, Huertas JR, Mataix JF, Villa RF, Gorini A (2000) Cerebral cortex synaptic heavy mitochondria may represent the oldest synaptic mitochondrial population: biochemical heterogeneity and effects of L-acetylcarnitine. J Bioenerg Biomembr 32, 163-173.
248. Collins TJ, Berridge MJ, Lipp P, Bootman MD (2002) Mitochondria are morphologically and functionally heterogeneous within cells. EMBO J 21, 1616-1627.
249. Muller M, Mironov SL, Ivannikov MV, Schmidt J, Richter DW (2005) Mitochondrial organization and motility probed by two-photon microscopy in cultured mouse brainstem neurons. Exp Cell Res 303, 114-127.
250. Huchzermeyer C, Albus K, Gabriel HJ, Ot́ahal J, Taubenberger N, Heinemann U, Kov́acs R, Kann O (2008) Gamma oscillations and spontaneous network activity in the hippocampus are highly sensitive to decreases in pO2 and concomitant changes in mitochondrial redox state. J Neurosci 28, 1153-1162.
251. Nicholls DG (2003) Bioenergetics and transmitter release in the isolated nerve terminal. Neurochem Res 28, 1433-1441.
252. Brown MR, Sullivan PG, Geddes JW (2006) Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria. J Biol Chem 281, 11658-11668.
253. Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25, 7278-7287.
254. Mattson MP, Keller JN, Begley JG (1998) Evidence for synaptic apoptosis. Exp Neurol 153, 35-48.
255. Xie J, Awad KS, Guo Q (2005) RNAi knockdown of Par-4 inhibits neurosynaptic degeneration in ALS-linked mice. J Neurochem 92, 59-71.
256. Finn JT,Weil M, Archer F, Siman R, Srinivasan A, Raff MC (2000) Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. J Neurosci 20, 1333-1341.
257. Ikegami K, Koike T (2003) Non-apoptotic neurite degeneration in apoptotic neuronal death: pivotal role of mitochondrial function in neurites. Neuroscience 122, 617-626.
258. Rego AC, Oliveira CR (2003) Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 28, 1563-1574.
259. Messier C, Gagnon M (1996) Glucose regulation and cognitive functions: relation to Alzheimers disease and diabetes. Behav Brain Res 75, 1-11.
260. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, TsuiW, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J (2001) Prediction of cognitive decline in normal elderly subjects with 2-18F]fluoro-2-deoxy-D-glucose/poitron- emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98, 10966-10971.
261. Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimers disease. Eur J Pharmacol 490, 97-113.
262. Agostinho P, Caseiro P, Rego AC, Duarte EP, Cunha RA, Oliveira CR (2000) Adenosine modulation of D-3H]aspartate release in cultured retina cells exposed to oxidative stress. Neurochem Int 36, 255-265.
263. Almeida CG, de Mendonca A, Cunha RA, Ribeiro JA (2003) Adenosine promotes neuronal recovery from reactive oxygen species induced lesion in rat hippocampal slices. Neurosci Lett 339, 127-130.
264. Håberg A, Qu H, Haraldseth O, Unsgård G, Sonnewald U (2000) In vivo effects of adenosine A1 receptor agonist and antagonist on neuronal and astrocytic intermediary metabolism studied with ex vivo 13C NMR spectroscopy. J Neurochem 74, 327-333.
265. Hammer J, Qu H, Haberg A, Sonnewald U (2001) In vivo effects of adenosine A2 receptor agonist and antagonist on neuronal and astrocytic intermediary metabolism studied with ex vivo 13C NMR spectroscopy. J Neurochem 79, 885-892.
266. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330, 613-622.
267. Nash JE, Brotchie JM (2000) A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinsons disease. J Neurosci 20, 7782-7789.
268. Wirkner K, Gerevich Z, Krause T, Gunther A, Koles L, Schneider D, Norenberg W, Illes P (2004) Adenosine A2A receptor-induced inhibition ofNMDAandGABAA receptormediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacology 46, 994-1007.
269. Mogul DJ, Adams ME, Fox AP (1993) Differential activation of adenosine receptors decreases N-type but potentiates Ptype Ca2+ current in hippocampal CA3 neurons. Neuron 10, 327-334.
270. Goncalves ML, Cunha RA, Ribeiro JA (1997) Adenosine A2A receptors facilitate 45Ca2+ uptake through class A calcium channels in rat hippocampal CA3 but not CA1 synaptosomes. Neurosci Lett 238, 73-77.
271. Lopes LV, Cunha RA, Kull B, Fredholm BB, Ribeiro JA (2002) Adenosine A2A receptor facilitation of hippocampal synaptic transmission is dependent on tonic A1 receptor inhibition. Neuroscience 112, 319-329.
272. Marchi M, Raiteri L, Risso F, Vallarino A, Bonfanti A, Monopoli A, Ongini E, Raiteri M(2002) Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol 136, 434-440.
273. Marcoli M, Raiteri L, Bonfanti A, Monopoli A, Ongini E, Raiteri M, Maura G (2003) Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 45, 201-210.
274. Popoli P, Frank C, Tebano MT, Potenza RL, Pintor A, Domenici MR, Nazzicone V, Pezzola A, Reggio R (2003) Modulation of glutamate release and excitotoxicity by adenosine A2A receptors. Neurology 61(Suppl 6), S69-S71.
275. Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, Cunha RA (2005) Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem 92, 433-441.
276. Li XX, Nomura T, Aihara H, Nishizaki T (2001) Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci 68, 1343-1350.
277. Nishizaki T, Nagai K, Nomura T, Tada H, Kanno T, Tozaki H, Li XX, Kondoh T, Kodama N, Takahashi E, Sakai N, Tanaka K, Saito N (2002) A new neuromodulatory pathway with a glial contribution mediated via A2a adenosine receptors. Glia 39, 133-147.
278. Pintor A, Galluzzo M, Grieco R, Pezzola A, Reggio R, Popoli P (2004) Adenosine A2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J Neurochem 89, 152-156.
279. Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pezzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22, 1967-1975.
280. Brambilla R, Cottini L, Fumagalli M, Ceruti S, Abbracchio MP (2003) Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43, 190-194.
281. Saura J, Angulo E, Ejarque A, Casad́oV,Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R, Serratosa J (2005) Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95, 919-926.
282. Daŕe E, Schulte G, Karovic O, Hammarberg C, Fredholm BB (2007) Modulation of glial cell functions by adenosine receptors. Physiol Behav 92, 15-20.
283. Yu L, Shen HY, Coelho JE, Aráujo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J, Taylor D, Müller CE, Linden J, Cunha RA, Chen JF (2008) A2A receptors modulate motor activity and MPTP neurotoxicity by distinct cellular mechanisms. Ann Neurol 63, 338-346.
284. Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonca A (2007) Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 83, 310-331.
285. Cunha RA, Chen JF, Sitkovsky MV (2007) Opposite modulation of peripheral inflammation and neuroinflammation by adenosine A2A receptors. In: Interaction Between Neurons and Glia in Aging and Disease, (Malva JO, Rego AC, Cunha RA, Oliveira CR, Eds.), pp. 53-79, Springer-Verlag, Berlin.
286. Hindley S, Herman MA, Rathbone MP (1994) Stimulation of reactive astrogliosis in vivo by extracellular adenosine diphosphate or an adenosine A2 receptor agonist. J Neurosci Res 38, 399-406.
287. Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K, Popoli P (2007) Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol 66, 363-371.
288. Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF (2009) Adenosine A2A receptor mediates microglial process retraction. Nature Neurosci 12, 872-878.
289. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter PJ (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18, 152-160.
290. Brodie C, Blumberg PM, Jacobson KA (1998) Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 429, 139-142.
291. Li W, Dai S, An J, Xiong R, Li P, Chen X, Zhao Y, Liu P, Wang H, Zhu P, Chen JF, Zhou Y (2009) Genetic inactivation of adenosine A2A receptors attenuates acute traumatic brain injury in the mouse cortical impact model. Exp Neurol 215, 69-76.
292. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19, 312-318.
293. Carini R, Castino R, De Cesaris MG, Splendore R, D́emoz M, Albano E, Isidoro C (2004) Preconditioning-induced cytoprotection in hepatocytes requires Ca2+-dependent exocytosis of lysosomes. J Cell Sci 117, 1065-1077.
294. Liu J, Lu W, Reigada D, Nguyen J, Laties AM, Mitchell CH (2008) Restoration of lysosomal pH in RPE cells from cultured human and ABCA4(α/β) mice: pharmacologic approaches and functional recovery. Invest Ophthalmol Vis Sci 49, 772-780
295. Han ME, Park KH, Baek SY, Kim BS, Kim JB, Kim HJ, Oh SO (2007) Inhibitory effects of caffeine on hippocampal neurogenesis and function. Biochem Biophys Res Commun 356, 976-980.
296. Wentz CT, Magavi SSP (2009) Caffeine alters proliferation of neuronal precursors in the adult hippocampus. Neuropharmacology 56, 994-1000.
297. Díogenes MJ, Fernandes CC, Sebastião AM, Ribeiro JA (2004) Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci 24, 2905-2913.
298. Mojsilovic-Petrovic J, Jeong GB, Crocker A, Arneja A, David S, Russell DS, Kalb RG (2006) Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J Neurosci 26, 9250-9263.
299. Díogenes MJ, Assaife-Lopes N, Pinto-Duarte A, Ribeiro JA, Sebastião AM (2007) Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus 17, 577-585.
300. Costa MS, Botton PH, Mioranzza S, Ardais AP, Moreira JD, Souza DO, Porcíuncula LO (2008) Caffeine improves adult mice performance in the object recognition task and increases BDNF and TrkB independent on phospho-CREB immunocontent in the hippocampus. Neurochem Int 53, 89-94.
301. TebanoMT, Martire A, Potenza RL, GroC, PepponiR, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P (2008) Adenosine A2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem 104, 279-286.
302. Gomes, CARV, Simoes PF, Canas PM, Quiroz C, Sebastião AM, Ferŕe S, Cunha RA, Ribeiro JA (2009) GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A2A receptors. J Neurochem 108, 1208-1219.
303. Coney AM, Marshall JM (1998) Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. J Physiol 509, 507-518.
304. Ngai AC, Coyne EF, Meno JR, West GA, Winn HR (2001) Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles. Am J Physiol 280, H2329-H2335.
305. Kochanek PM, Hendrich KS, Jackson EK, Wisniewski SR, Melick JA, Shore PM, Janesko KL, Zacharia L, Ho C (2005) Characterization of the effects of adenosine receptor agonists on cerebral blood flow in uninjured and traumatically injured rat brain using continuous arterial spin-labeled magnetic resonance imaging. J Cereb Blood Flow Metab 25, 1596-1612.
306. Reiss AB, Rahman MM, Chan ES, Montesinos MC, Awadallah NW, Cronstein BN (2004) Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leukoc Biol 76, 727-734.
307. Boison D (2006) Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci 27, 652-658.
308. Boison D (2008) Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol 8, 2-7.
309. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Smoking, alcohol, and coffee consumption preceding Parkinsons disease: a case-control study. Neurology 55, 1350-1358.
310. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA (2006) Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsons disease. J Neurosci 26, 535-541.
311. Adan A, Prat G, Fabbri M, Sanchez-Turet M (2008) Early effects of caffeinated and decaffeinated coffee on subjective state and gender differences. Prog Neuropsychopharmacol Biol Psychiatry 32, 1698-1703.
312. Jones FS, Jing J, Stonehouse AH, Stevens A, Edelman GM (2008) Caffeine stimulates cytochrome oxidase expression and activity in the striatum in a sexually dimorphic manner. Mol Pharmacol 74, 673-684.
313. Killgore WD, Muckle AE, Grugle NL, Killgore DB, Balkin TJ (2008) Sex differences in cognitive estimation during sleep deprivation: effects of stimulant countermeasures. Int J Neurosci 118, 1547-1557.
314. Noschang CG, Pettenuzzo LF, von Pozzer Toigo E, Andreazza AC, Krolow R, Fachin A, Avila MC, Arcego D, Crema LM, Diehl LA, Goncalvez CA, Vendite D, Dalmaz C (2009) Sex-specific differences on caffeine consumption and chronic stress-induced anxiety-like behavior and DNA breaks in the hippocampus. Pharmacol Biochem Behav 94, 63-69.
315. Blokland A, Schreiber R, Prickaerts J (2006) Improving memory: a role for phosphodiesterases. Curr Pharm Des 12, 2511-2523.
316. Nicholson CD, Challiss RA, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12, 19-27.
317. Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, Chao MV, Sendtner M (2007) Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc Natl Acad Sci U S A 104, 17210-17215.
318. Cunha RA, Milusheva E, Vizi ES, Ribeiro JA, Sebastião AM (1994) Excitatory and inhibitory effects of A1 and A2A adenosine receptor activation on the electrically evoked 3H]acetylcholine release from different areas of the rat hippocampus. J Neurochem 63, 207-214.
319. Cunha RA, Johansson B, Fredholm BB, Ribeiro JA, Sebastião AM (1995) Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci Lett 196, 41-414.
320. van Dort CJ, Baghdoyan HA, Lydic R (2009) Adenosine A1 and A2A receptors in mouse prefrontal cortex modulate acetylcholine release and behavioral arousal. J Neurosci 29, 871-881.
321. Corradetti R, Pedata F, Pepeu G, Vannucchi MG (1986) Chronic caffeine treatment reduces caffeine but not adenosine effects on cortical acetylcholine release. Br J Pharmacol 88, 671-676.
322. Pedata F, Giovannelli L, De Sarno P, Pepeu G (1986) Effect of adenosine, adenosine derivatives, and caffeine on acetylcholine release from brain synaptosomes: interaction with muscarinic autoregulatory mechanisms. J Neurochem 46, 1593-1598.